Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations

BACKGROUND: EGFR and ALK alternations often contribute to human malignancies, including lung cancer. EGFR and ALK mutations are usually sensitive to EGFR-tyrosine kinase inhibitors (TKIs) and ALK-TKIs. Although generally mutually exclusive, these mutations do co-exist in rare cases. This study inves...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Xiaodan, Zhong, Jia, Yu, Zhuo, Zhuo, Minglei, Zhang, Min, Chen, Rongrong, Xia, Xuefeng, Zhao, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520304/
https://www.ncbi.nlm.nih.gov/pubmed/34654390
http://dx.doi.org/10.1186/s12885-021-08824-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520304/
https://www.ncbi.nlm.nih.gov/pubmed/34654390
http://dx.doi.org/10.1186/s12885-021-08824-2

Ejemplares similares